Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy -: A status report

被引:55
作者
Balfour, D
Benowitz, N
Fagerström, K
Kunze, M
Keil, U
机构
[1] Univ Munster, Inst Epidemiol & Social Med, Fac Med, D-48129 Munster, Germany
[2] Univ Dundee, Sch Med, Dept Pharmacol & Neurosci, Dundee, Scotland
[3] Univ Calif San Francisco, San Francisco Gen Hosp, Clin Pharmacol Unit, Med Serv, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA
[7] Fagerstrom Consulting, S-25225 Helsingborg, Sweden
[8] Univ Vienna, Inst Social Med, Vienna, Austria
关键词
tobacco dependence; smoking cessation; nicotine replacement therapy;
D O I
10.1053/euhj.1999.1949
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tobacco use is a global health care problem. Repetitive exposure to nicotine produces neuroadaptation resulting in nicotine dependence. Cigarette smoking is particularly addictive due to the repeated delivery of bolus doses of nicotine to the bloodstream. Although compulsive tobacco use is sustained by nicotine addiction, it is the toxic combustion products in tobacco smoke such as carbon monoxide and oxidant gases that adversely affect the cardiovascular system. Smoking cessation produces significant health benefits and is a very cost-effective intervention. Evidence that nicotine is the addictive component of tobacco provides the rationale for using nicotine replacement therapy to aid cessation. Nicotine replacement therapy doubles successful smoking cessation fates and evidence-based guidelines for the treatment of tobacco addiction recommend routine use of nicotine replacement therapy, particularly in heavily dependent smokers. Success rates of up to 40% can be achieved in specialist clinics. Despite early concerns regarding the safety of nicotine replacement therapy in smokers with heart disease, it is now clear that the health risks of using nicotine replacement therapy to assist such patients to stop, or significantly reduce, smoking far outweigh any treatment-related risks. (C) 2000 The European Society of Cardiology.
引用
收藏
页码:438 / 445
页数:8
相关论文
共 50 条
[11]   EVIDENCE THAT TOBACCO SMOKING INCREASES THE DENSITY OF (-)-[H-3]NICOTINE BINDING-SITES IN HUMAN-BRAIN [J].
BENWELL, MEM ;
BALFOUR, DJK ;
ANDERSON, JM .
JOURNAL OF NEUROCHEMISTRY, 1988, 50 (04) :1243-1247
[12]   SMOKING-ASSOCIATED CHANGES IN THE SEROTONERGIC SYSTEMS OF DISCRETE REGIONS OF HUMAN BRAIN [J].
BENWELL, MEM ;
BALFOUR, DJK ;
ANDERSON, JM .
PSYCHOPHARMACOLOGY, 1990, 102 (01) :68-72
[13]   EFFECTS OF NICOTINE ADMINISTRATION AND ITS WITHDRAWAL ON PLASMA-CORTICOSTERONE AND BRAIN 5-HYDROXYINDOLES [J].
BENWELL, MEM ;
BALFOUR, DJK .
PSYCHOPHARMACOLOGY, 1979, 63 (01) :7-11
[14]   THE EFFECTS OF NICOTINE ADMINISTRATION ON 5-HT UPTAKE AND BIOSYNTHESIS IN RAT-BRAIN [J].
BENWELL, MEM ;
BALFOUR, DJK .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 84 (1-2) :71-77
[15]   CONTROLLED TRIAL OF NICOTINE POLACRILEX GUM WITH SUPPORTIVE MEASURES [J].
BLONDAL, T .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (08) :1818-1821
[16]   Coronary risk factors and plaque morphology in men with coronary disease who died suddenly [J].
Burke, AP ;
Farb, A ;
Malcom, GT ;
Liang, YH ;
Smialek, J ;
Virmani, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1276-1282
[17]   DOPAMINERGIC MECHANISMS IN THE LOCOMOTOR STIMULANT EFFECTS OF NICOTINE [J].
CLARKE, PBS .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (07) :1427-1432
[18]   THE MESOLIMBIC DOPAMINERGIC SYSTEM IS IMPLICATED IN THE REINFORCING EFFECTS OF NICOTINE [J].
CORRIGALL, WA ;
FRANKLIN, KBJ ;
COEN, KM ;
CLARKE, PBS .
PSYCHOPHARMACOLOGY, 1992, 107 (2-3) :285-289
[19]   NICOTINE MAINTAINS ROBUST SELF-ADMINISTRATION IN RATS ON A LIMITED-ACCESS SCHEDULE [J].
CORRIGALL, WA ;
COEN, KM .
PSYCHOPHARMACOLOGY, 1989, 99 (04) :473-478
[20]  
DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414